On the other hand, it has been suggested that both OCT4 and SOX2 expression are associated with early tumor stage and better disease-free survival, raising the possibility that both SOX2 and OCT4 might not be the best targets to eradicate tumor relapse and progression [57]. The gene discussed is POU5F1; the disease is neoplasm.